|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
ATE173159T1
(de)
|
1992-03-25 |
1998-11-15 |
Depomed Systems Inc |
Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
WO1997047285A1
(en)
|
1996-06-10 |
1997-12-18 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
CA2290624C
(en)
|
1997-06-06 |
2006-12-05 |
John W. Shell |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
CA2389236A1
(en)
|
1999-11-02 |
2001-05-10 |
Depomed, Inc. |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
|
ES2270982T3
(es)
|
2000-02-04 |
2007-04-16 |
Depomed, Inc. |
Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
EP1343782B1
(en)
|
2000-12-21 |
2009-05-06 |
SmithKline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
|
JP2004532259A
(ja)
|
2001-05-29 |
2004-10-21 |
デポメッド ディベロップメント リミティド |
胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
JP2005508358A
(ja)
|
2001-10-25 |
2005-03-31 |
デポメド・インコーポレイテッド |
胃滞留型ロサルタン投与量を用いる治療方法
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
WO2008080153A2
(en)
*
|
2006-12-22 |
2008-07-03 |
The Children's Hospital Of Philadelphia |
A novel protein kinase c therapy for the treatment of acute lung injury
|
|
WO2009014633A1
(en)
*
|
2007-07-20 |
2009-01-29 |
Trustees Of The University Of Pennsylvania |
Method of treating acute respiratory distress syndrome
|
|
EP3050566B1
(en)
|
2007-09-10 |
2018-11-28 |
Boston Biomedical, Inc. |
A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
|
|
CA2753844A1
(en)
*
|
2008-03-05 |
2009-09-11 |
Vicus Therapeutics, Llc |
Compositions and methods for mucositis and oncology therapies
|
|
US8652476B2
(en)
|
2009-07-27 |
2014-02-18 |
Niigata University |
Pharmaceutical composition for treating ischemic events
|
|
JP5823672B2
(ja)
|
2009-07-27 |
2015-11-25 |
国立大学法人 新潟大学 |
受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
|
|
US20120107304A1
(en)
*
|
2010-04-27 |
2012-05-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy in treatment of oncological and fibrotic diseases
|
|
EP2640384A1
(en)
|
2010-11-18 |
2013-09-25 |
Synta Pharmaceuticals Corp. |
Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
|
|
WO2012118632A1
(en)
|
2011-02-28 |
2012-09-07 |
Ning Xi |
Substituted quinoline compounds and methods of use
|
|
EP2699572B1
(en)
|
2011-04-21 |
2016-08-10 |
Origenis GmbH |
Heterocyclic compounds as kinase inhibitors
|
|
CA2852912A1
(en)
|
2011-10-31 |
2013-05-10 |
Glaxosmithkline Intellectual Property Limited |
Pazopanib formulation
|
|
BR112014016299A8
(pt)
|
2011-12-30 |
2017-07-04 |
Abbvie Inc |
imunoglobulinas de domínio variável e usos das mesmas
|
|
WO2013148537A1
(en)
*
|
2012-03-29 |
2013-10-03 |
Ning Xi |
Substituted spirobicyclic compounds and methods of use
|
|
JP6799201B2
(ja)
|
2013-07-31 |
2020-12-16 |
アヴァリン ファーマ インク． |
エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
|
|
JP2016530210A
(ja)
|
2013-09-17 |
2016-09-29 |
ファーマケア，インク． |
ヘテロ環式ビニルオートタキシン阻害剤化合物
|
|
AU2014324566B2
(en)
*
|
2013-09-30 |
2019-01-24 |
The Texas A&M University System |
Compositions associated with and methods of managing neutrophil movement
|
|
KR101636563B1
(ko)
*
|
2014-01-24 |
2016-07-06 |
주식회사 엘지생명과학 |
급성 폐 손상 및 급성 호흡곤란 증후군의 예방 또는 치료용 조성물
|
|
WO2015164161A1
(en)
*
|
2014-04-22 |
2015-10-29 |
Calitor Sciences, Llc |
Bicylcic pyrazolone compounds and methods of use
|
|
BR112017002466A2
(pt)
|
2014-08-08 |
2017-12-05 |
Forsight Vision4 Inc |
formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação
|
|
JP7108018B2
(ja)
|
2017-04-17 |
2022-07-27 |
イエール ユニバーシティ |
急性肺傷害を処置または予防する化合物、組成物および方法
|